TKIs治疗Ph染色体阳性急性淋巴细胞白血病的治疗进展

李军民; 周励

doi:10.13201/j.issn.1004-2806.2016.03.003

TKIs治疗Ph染色体阳性急性淋巴细胞白血病的治疗进展

李军民^,,
周励

- 上海交通大学医学院附属瑞金医院血液科(上海, 200025)

详细信息

通讯作者: 李军民,E-mail:lijunmin@medmail.com.cn

中图分类号: R733.71

收稿日期: 2016-02-16

Progress on TKIs in the treatment of Ph chromosome positive acute lymphoblastic leukemia

LI Junmin^,,
ZHOU Li

More Information

Corresponding author: LI Junmin, E-mail: lijunmin@medmail.com.cn

Received Date: 16 February 2016

摘要

- 白血病,淋巴细胞,急性 /
- 酪氨酸激酶抑制剂
- acute lymphoblastic leukemia /
- tyrosine kinase inhibitor

HTML全文

参考文献(30)

[1]	Leoni V,Biondi A.Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia[J].Haematological,2015,100:295-299.
[2]	Ribera JM.Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia:how to best use all the available tools[J].Leuk Lymphoma,2013,54:21-27.
[3]	Lee HJ,Thompson JE,Wang ES,et al.Philadelphia chromosome-positive acute lymphoblastic leukemia:current treatment and future perspectives[J].Cancer,2011,117:1583-1594.
[4]	Thomas DA,Faderl S,Cortes J,et al.Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate[J].Blood,2004,103:4396-4407.
[5]	Dombret H,Gabert J,Boiron JM,et al.Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia——results of the prospective multicenter LALA-94 trial[J].Blood,2002,100:2357-2366.
[6]	Fielding AK,Rowe JM,Richards SM,et al.Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era:results from the International ALL Trial MRC UKALLXII/ECOG2993[J].Blood,2009,113:4489-4496.
[7]	Aricò M,Schrappe M,Hunger SP,et al.Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005[J].J Clin Oncol,2010,28:4755-4761.
[8]	Marks DI,Wang T,Pérez WS,et al.The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission[J].Blood,2010,116:366-374.
[9]	Vignetti M,Fazi P,Cimino G,et al.Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy:results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol[J].Blood,2007,109:3676-3678.
[10]	Foà R,Vitale A,Vignetti M,et al.Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia[J].Blood,2011,118:6521-6528.
[11]	Jabbour E,O'Brien S,Konopleva M,et al.New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia[J].Cancer,2015,121:2517-2528.
[12]	Pfeifer H,Goekbuget N,Volp C,et al.Long-term outcome of 335 patients receiving different schedules of imatinib and chemotherapy as front-line treatment for Philadelphia-positive acute lymphoblastic leukemia (Ph⁺ ALL)[abstract].Blood,2010,116:173.
[13]	Wassmann B,Pfeifer H,Goekbuget N,et al.Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph⁺ ALL)[J].Blood,2006,108:1469-1477.
[14]	Li Y,Zou DH,Zhao YZ,et al.Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia:a single center study from China[J].Leuk Lymphoma,2010,51:488-496.
[15]	Ottman OG,Pfeifer H,Cayuela JM,et al.Nilotinib (Tasigna) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia chromosome/BCR-ABL1 positive acute lymphoblastic leukemia (ALL):a trial of the European Working Group for Adult ALL (EWALL-PH-02)[abstract].Blood,2014,124:798.
[16]	Rousselot P,Coude MM,Huguet F,et al.Dasatinib and low intensity chemotherapy for first-line treatment in patients with de novo Philadelphia positive ALL aged 55 and over:final results of the EWALL-Ph-01 study[abstract].Blood,2012,120(suppl 1):666.
[17]	Chiaretti S,Vitale A,Elia L,et al.First results of the multicenter total therapy GIMEMA LAL 1509 protocol for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) patients[abstract].Blood,2014,124:797.
[18]	O'Hare T,Shakespeare WC,Zhu X,et al.AP24534,a pan-BCR-ABL inhibitor for chronic myeloid leukemia,potently inhibits the T315I mutant and overcomes mutation-based resistance[J].Cancer Cell,2009,16:401-412.
[19]	Cortes JE,Kantarjian H,Shah NP,et al.Ponatinib in refractory Philadelphia chromosome-positive leukemias[J].N Engl J Med,2012,367:2075-2088.
[20]	Yu GP,Xu D,Liu QF,et al.Comparison of the efficacy of the first and second-generation tyrosine kinase inhibitors in the first line treatment of Ph-positive acute lymphoblastic leukemia[abstract].Blood,2015,126:1302-1302.
[21]	Tanguy-Schmidt A,Rousselot P,Chalandon Y,et al.Long-term follow up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia:a GRAALL study[J].Biol Blood Marrow Transplant,2013,19:150-155.
[22]	Brissot E,Labopin M,Beckers MM,et al.Tryosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia[J].Hematological,2015,100:392-399.
[23]	Mizuta S,Matsuo K,Yagasaki F,et al.Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia[J].Leukemia,2011,25:41-47.
[24]	Pfeifer H,Wassmann B,Bethge W,et al.Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia[J].Leukemia,2013,27:1254-1262.
[25]	Ram R,Storb R,Sandmaier BM,et al.Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia[J].Haematologica,2011,96:1113-1120.
[26]	Lee S,Kim DW,Cho B,et al.Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation:the potential of real-time quantitative reverse-transcription polymerase chain reaction[J].Br J Haematol,2003,120:145-153.[CM (79.5mm]
[27]	Bachanova V,Marks DI,Zhang MJ,et al.Ph+ALL patients in first complete remission have similar survival after reduced intensity and myeloblastive allogeneic transplantation:impact of tryrosine kinase inhibitor and minimal residual disease[J].Leukemia,2014,28:658-665.
[28]	Schlegel P,Lang P,Zugmaier G,et al.Pediatric post-transplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab[J].Haematologica,2014,99:1212-1219.
[29]	Leonard J,Rowley J,Hayes-Lattin B,et al.Dual targeting of Ph+ALL with Dasatinib and ABT-199(Venetoclax)[abstract].Blood,2015,126:1329-1329.
[30]	Churchman ML,Jones L,Evans K,et al.Efficacy of focal adhesion inhibition in combination with Dasatinib in BCL-ABL1 acute lymphoblastic leukemia[abstract].Blood,2015,126:3766-3766.